DxS has won a coveted 'Biotechnology Project of the Year' award for its highly sensitive EGFR (epidermal growth factor receptor) mutation test kit
Sponsored by the Manchester based law firm Pannone, the award was presented by Bionow, the UK Northwest Regional Development Agency's (NWDA) biotechnology cluster support group, at the agency's annual awards ceremony in Cheshire, UK.
The award scheme aims to showcases the very best of biotechnology in the region, which is home to some of the country's most innovative biomedical companies.
Recent advances in the field of cancer drugs have provided DxS with an opportunity to use its scientific and commercial strengths to develop the world's first tumour mutation analysis kit to identify patients who will respond well to certain lung cancer therapies.
This new oncogene assay can detect the 29 most common somatic mutations in the epidermal growth factor receptor gene, identifying mutations that are not visible by sequencing techniques.
Commenting on the receipt of the award, Stephen Little, CEO of DxS, said: "We are delighted to receive this award as it acknowledges the hard work that has gone into developing such a ground-breaking technology.
"DxS has created a novel clinically valuable diagnostic kit that offers un-rivalled sensitivity and selectivity over previous methods".
Simon Wallwork, corporate partner at Pannone, adds, "We are pleased to be able to support the innovative work of North West based biotechnology companies, such as DxS.
"With a biotech client base of over 20 companies, Pannone's understand the work involved in commercialising a scientific idea into a successful product".
Pannone is a Manchester based legal firm with a dedicated life science division.
